The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy.

摘要: The modulation of DNA repair pathways for therapeutic benefit in cancer has now become a reality with the development poly (ADP-ribose) polymerase inhibitors (PARPi). PARP is involved single-strand breaks, which presence defective homologous recombination lead to double-strand most lethal form damage. These agents therefore may be drugs choice BRCA mutant breast and ovarian cancers. PARPi result synergistic antitumor effects when combined cisplatin, temozolomide, topoisomerase ionizing radiation. indications lie beyond mutations include genomic functional defects damage response pathways. Several are clinical phase at this time and, given recent failure III trial iniparib triple-negative cancer, identification structural differences between these becomes critical. Acquired resistance being noted represents an important limitation field. A concise review literature field presented.